HK Stock Market Move | IMPACT THERAP-B (07630) rose over 3%, with expectations that its mid-term losses will decrease by approximately 22% to 37% year-on-year. IMP2794 has been nominated for PPC.

IMPACT THERAP-B (07630) rose over 3%, and as of the time of publication, it was up 2.64%, priced at HKD 12.43, with a trading volume of HKD 3.0636 million. In news, IMPACT THERAP-B recently announced that, based on the Board of Directors' preliminary assessment of the unaudited consolidated management accounts for the six months ending June 30, 2026 (the relevant period) and the information currently available to the Board, the Group expects to achieve: revenue of approximately RMB 94.7 million to RMB 116 million, an increase of about 276% to 359% compared to approximately RMB 25.2 million for the same period ending June 30, 2025; and a loss of approximately RMB 81.7 million to RMB 99.9 million during the period, a decrease of about 37% to 22% compared to approximately RMB 129 million for the same period. Additionally, IMPACT THERAP-B announced that the company has nominated IMP2794 as a preclinical candidate compound (PCC), which is a KAT6A-specific degradable PROTAC. IMP2794 is the first PCC discovered by the company using its proprietary targeted protein degradation platform. IMP2794 is a highly effective and selective degrader of KAT6A, with over 1000-fold selectivity for KAT6B. Notably, IMP2794 has shown extremely high oral bioavailability in various rodent and non-rodent animal models, suggesting that it may achieve ideal drug exposure in humans.